Full-Year 2023 Total Revenue Growth of 20% to $197.5 Million, with Adjusted EBITDA Growth of 40% Fourth Quarter Total Revenue Growth of 23% to $65.0 Million, with Adjusted EBITDA Growth of 50% .
MediWound (NASDAQ:MDWD – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Monday. Separately, HC Wainwright raised their price target on shares of MediWound from $26.00 to $28.00 and gave the company a “buy” rating in a […]
CAMBRIDGE, Mass., Feb. 27, 2024 Vericel Corporation , a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO.
Get latest articles and stories on India at LatestLY. The Bharat Serums and Vaccines (BSV), a biopharmaceutical company in India, inked an exclusive distribution agreement with MediWound (NASDAQ: MDWD) in December 2022 to introduce NexoBrid, a groundbreaking treatment for severe burns, in the Indian market. India News | Nexobrid: A Revolutionary Treatment for Burns to Treat Patients in Few Hours.